A

Armata Pharmaceuticals Inc
AMEX:ARMP

Watchlist Manager
Armata Pharmaceuticals Inc
AMEX:ARMP
Watchlist
Price: 1.94 USD -0.51% Market Closed
Market Cap: 70.2m USD
Have any thoughts about
Armata Pharmaceuticals Inc?
Write Note

Armata Pharmaceuticals Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Armata Pharmaceuticals Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
A
Armata Pharmaceuticals Inc
AMEX:ARMP
Accrued Liabilities
$6.9m
CAGR 3-Years
27%
CAGR 5-Years
20%
CAGR 10-Years
33%
Abbvie Inc
NYSE:ABBV
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accrued Liabilities
$14.6B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accrued Liabilities
$3.2B
CAGR 3-Years
27%
CAGR 5-Years
22%
CAGR 10-Years
28%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accrued Liabilities
$2.5B
CAGR 3-Years
7%
CAGR 5-Years
25%
CAGR 10-Years
24%
No Stocks Found

Armata Pharmaceuticals Inc
Glance View

Market Cap
70.2m USD
Industry
Biotechnology

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

ARMP Intrinsic Value
2.18 USD
Undervaluation 11%
Intrinsic Value
Price
A

See Also

What is Armata Pharmaceuticals Inc's Accrued Liabilities?
Accrued Liabilities
6.9m USD

Based on the financial report for Sep 30, 2024, Armata Pharmaceuticals Inc's Accrued Liabilities amounts to 6.9m USD.

What is Armata Pharmaceuticals Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
33%

Over the last year, the Accrued Liabilities growth was -57%. The average annual Accrued Liabilities growth rates for Armata Pharmaceuticals Inc have been 27% over the past three years , 20% over the past five years , and 33% over the past ten years .

Back to Top